Sana Kliniken AG Signs Agreement With Masimo, Giving One of Germany's Largest Private Hospital Networks Access to Masimo's Advanced Noninvasive Patient Monitoring Solutions

IRVINE, California, March 7, 2012 /PRNewswire/ --

- Deal Enables Sana to Move Toward a Standardized Oximetry Technology for Connected Hospitals

Sana Kliniken AG, a cooperative of 47 owned/partly owned and managed private hospitals as well as more than 450 purchasing cooperation partners throughout Germany, and Masimo (NASDAQ: MASI) jointly announce a pulse oximetry supplier agreement that makes Masimo's full line of noninvasive patient monitoring solutions available on Sana Kliniken's medical equipment purchasing contract.  Now, in addition to Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry solutions, all hospitals owned, managed, and contracted with Sana Kliniken AG will also be able to access and purchase the Masimo rainbow® SET Pulse CO-Oximeters and sensors offering advanced noninvasive physiological measurements at significant contracted savings.

"As one of Germany's leading hospital networks of acute and specialized medical services, the strength of the care we provide relies on the high-quality clinical expertise and leading medical equipment solutions we employ," said Olaf Buhr, head of strategic purchasing at Sana Kliniken AG. "We believe that Masimo rainbow SET technology uniquely positions our affiliated hospitals to better care for today's patient populations and cost-effectively prepares them for the future challenges facing health care."

Effective January 1, 2012 through January 1, 2016, Sana Kliniken member hospitals can purchase Masimo standalone (Radical-7®, Rad-87®, Rad-8) and portable (Rad-5, Rad-57®,  Pronto, Pronto-7™) rainbow SET Pulse CO-Oximeters on contract, along with ReSposable, single patient use/disposable, and reusable sensors for all categories of patients (from neonatal and infant/pediatric to adult).

Masimo rainbow SET Pulse CO-Oximetry™ is a breakthrough technology platform that allows hospitals to noninvasively measure and continuously monitor blood constituents and physiological parameters that previously required invasive procedures, including: total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and acoustic respiration rate (RRa™), in addition to the Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR). The oximetry standard-of-care at leading hospitals worldwide, Masimo rainbow SET provides real-time results that enable clinicians to more rapidly assess patients and detect and treat potentially life-threatening conditions earlier.

At the heart of the Masimo rainbow SET technology platform is Masimo SET® (Signal Extraction Technology), clinically proven in more than 100 independent studies to provide accurate and reliable SpO2 and pulse rate measurements, even under the most challenging conditions of patient motion and low peripheral perfusion. In doing so, Masimo SET has been shown to reduce false patient monitor alarms by over 95% and expand true alarm detection to over 97%-making it the leading Measure-Through Motion and Low Perfusion SpO2 solution incorporated into more than 100 multi-parameter monitors and 50 monitoring brands.

As an upgradeable oximetry technology platform enabling new device capabilities to be added through simple field-installed software upgrades, Masimo rainbow Pulse CO-Oximeters allow healthcare facilities to fight the rising costs of equipment obsolescence. Instead of costly device and hardware replacements, new noninvasive measurements and patient monitoring capabilities can be cost-effectively added to existing "rainbow-ready" Masimo oximeters via a quick and easy field-installed software upgrader tool.

Masimo Founder and CEO, Joe Kiani said, "Representing one of Germany's largest private hospital networks, we are pleased that Sana Kliniken has chosen to make Masimo's full line of Masimo SET and Masimo rainbow SET oximetry solutions available to all its member hospitals. This agreement will ensure that access to the most advanced noninvasive patient monitoring solutions is available for the medical care and treatment of patients throughout Germany." 

*To see a summary of all known clinical studies and abstracts on Masimo technologies and noninvasive measurements, please visit: http://www.masimo.com/cpub/clinicals.htm.

About Sana Kliniken AG

Sana Kliniken AG consists of 47 owned hospitals and over 450 purchasing cooperation partners caring for more 1.334.000 patients. In addition to the core business of acute medicine, Sana includes specialist clinics is in the promising indications of heart/cardiovascular, orthopedics, and Neurology, as well as clinics and elder care facilities. This network of integrated health care is different from other private competitors as there are 31 private health insurers behind Sana.  For more information, visit:  http://www.sana.de

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events.  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices.  Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world.  Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at http://www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to:  risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb®), PVI®, acoustic respiration rate (RRa™), and SEDLine® contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at http://www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

    Media Contacts:

    Susanne Heintzmann                   Mike Drummond

    Sana Kliniken AG                     Masimo Corporation

    Phone: +089-678204-334               Phone: +1-949-297-7434

    Email: susanne.heintzmann@sana.de    Email: mdrummond@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care...by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine  are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.